Special Session

EDU 22 - Recruitment to Difficult Randomized Clinical Trials: Lessons from PARTiQoL, VALOR, and ProtecT

8:00 AM - 9:00 AM
Location: Room W196

Session Type: Education
1.00 AMA PRA Category 1 Credits™
1.00 CAMPEP Credits
1.00 MDCB Credits

- Overview of session, and brief explanation of evidence underpinning the session's content

Lessons from PARTIQoL
- Describe the recruitment challenges of this NCI-funded phase III RCT of Proton Therapy vs IMRT for prostate cancer, and how they are being addressed and overcome.

Lessons from VALOR
- Describe the recruitment challenges of this VA-sponsored phase III RCTs of Surgery vs SBRT for stage I lung cancer, and the methods that have contributed to it's successful recruitment.

Lessons from ProtecT
- Describe the strategies developed at the University of Bristol that helped complete the first successful phase III RCT of Surgery vs Radiotherapy vs Active Monitoring for prostate cancer (n=1,600, NEJM 2016).
- Describe the QuinteT Recruitment Intervention (QRI) model that was used for ProtecT, and how it has helped other difficult RCTs that were close to early termination turn around its accrual, and successfully complete. (QRI is now in >25 RCTs around the world).

- Provide attendees an opportunity to discuss concerns/queries about particular RCTs they are working on, and ways in which the techniques discussed in the session may be applied to address these.

Learning Objectives:


Drew Moghanaki, MD, MPH

Veterans Affairs - Atlanta

Atlanta VA Health Care System: Chief, Radiation Oncology: Employee;
Emory University School of Medicine: Acting Associate Professor: Employee

Varian Medical Systems: Honoraria

Association of VA Hematology Oncology: Board member, Chair research committee; ASTRO: Chair; Lung Cancer Alliance: Medical and Professional Advisory Board;
Lungevity Foundation: Scientific Advisory Board

Drew Moghanaki, MD, MPH
Hunter Holmes McGuire VA Medical Center
Richmond, Virginia - USA

I am a radiation oncologist who directs the clinical research program at the VA medical center in Richmond, Virginia. I have a passion for multi-disciplinary care, and thus serve as a member, scientific advisor, and chair of multiple national committees for the American Cancer Society, Lung Cancer Alliance, LUNGevity Foundation, and ASTRO. I am a co-chair for the VALOR phase III lung cancer Surgery vs SBRT trial, which is sponsored by the VA Cooperative Studies Program. I also am the principal investigator for the VA-PALS lung screening project which is adopitng the I-ELCAP management system for implementation at 10 VA medical centers to increase the number of lung cancer patients diagnosed at an early stage.


Send Email for Drew Moghanaki


EDU 22 - Recruitment to Difficult Randomized Clinical Trials: Lessons from PARTiQoL, VALOR, and ProtecT

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for EDU 22 - Recruitment to Difficult Randomized Clinical Trials: Lessons from PARTiQoL, VALOR, and ProtecT